Iterum Therapeutics (ITRM)
(Delayed Data from NSDQ)
$1.01 USD
+0.01 (0.90%)
Updated Oct 4, 2024 03:59 PM ET
After-Market: $1.00 -0.01 (-0.50%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
ITRM 1.01 +0.01(0.90%)
Will ITRM be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ITRM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ITRM
ITRM Posts Updates From FDA Advisory Meeting for UTI Drug, Stock Down
Iterum (ITRM) Plans Early Submission of UTI Drug NDA, Stock Up
ITRM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Avalo (AVTX) Fails to Meet Goal in Asthma Study, Stock Down 89%
Catalyst (CPRX) to Gain DMD Drug Licensing Rights From Santhera
Beat the Market the Zacks Way: Uber, VirTra, Oracle in Focus
Other News for ITRM
Iterum stock falls 9% in wake of FDA AdComm meeting on UTI drug
Iterum provides update on FDA advisory committee discussion on oral sulopenem
Iterum Therapeutics Provides Update on FDA Advisory Committee Discussion of Oral Sulopenem for the Treatment of uUTI in Adult Women
Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference
Iterum Therapeutics plc (ITRM) Q2 2024 Earnings Call Transcript